3/16/2026

Korea Inc. Rushes Governance Changes as Shareholder Meetings Begin

Korea Herald (03/16/26) Sung-mi, Ahn

South Korea’s shareholder meeting season starts this week, with major conglomerates such as Samsung Electronics (KRX: 005930) and Hyundai Motor Group (KRX: 005380) convening annual general meetings that will focus on governance changes and corporate strategies. This year’s meetings are drawing heightened attention, with business groups rushing to amend bylaws and bolster management control before revisions to the Commercial Act take effect in the second half of the year. As major conglomerates view upcoming meetings as a final chance to adjust rules in ways that favor controlling shareholders, tensions are expected to rise between corporate leadership and activist investors. According to the Korea Securities Depository on Monday, a total of 211 listed firms will hold annual meetings this week alone — including 102 companies on the main Kospi board and 107 on the Kosdaq market — making it a highly concentrated period that market watchers have dubbed “shareholder meeting super week.” The lineup includes some of the country’s largest companies. Hyundai Mobis (KRX: 012330) will kick off the week on Tuesday, followed by meetings on Wednesday at Samsung Electronics, Samsung SDI (KRX: 006400), and Samsung Electro-Mechanics (KRX: 009150). Next week, more companies are slated to hold meetings, including Korea Zinc (KRX: 010130)—currently in the midst of a heated management control battle. Corporate governance restructuring stands out as the dominant agenda this year, as companies move to get ahead before amendments to the Commercial Act take effect, a set of rules that aim to strengthen oversight of corporate boards and rights of minority shareholders. From July 23, top shareholders and related parties will have their voting rights capped at 3% when electing audit committee members. Starting Sept. 10, companies will also face mandatory cumulative voting and will have to increase the number of separately elected audit committee members from one to two. In response, many companies are preemptively adjusting their boardroom structures before the rules take effect. Samsung Electronics and Samsung SDS (KRX: 018260) are proposing to replace fixed three-year director terms with a more flexible “within three years” structure. Hanwha (KRX: 000880) affiliates seek to extend terms from “within two years” to “three years or within three years.” Governance advocates argue that such flexibility allows director terms to be spread out on a case-by-case basis, reducing the number of seats up for election at any given meeting. This would lower the odds of minority shareholder-backed candidates securing board seats under cumulative voting rules. Meanwhile, some major companies are moving to cut the maximum number of board members and then nominating exactly that number. With no vacant seats, alternative slates are effectively blocked, making it difficult for minority shareholders to gain board seats. Hyosung Group (KRX: 004800) affiliates have proposed reducing board caps from 16 directors to seven to nine, while Hanwha Galleria (KRX: 452260) seeks to shrink its board from 13 to seven, and LS Electric (KRX: 010120) from nine to five. Beyond governance reforms and shareholder return policies, this year’s meetings are also expected to cover business strategies and future visions. At Samsung Electronics, shareholders will likely focus on the outlook for the semiconductor division, particularly the company’s standing in high-bandwidth memory chips, as well as foundry investments and the possibility of special dividends following the recent rebound in performance. Hyundai Mobis will put Executive Chair Chung Euisun’s reappointment as an inside director to a shareholder vote. Hyundai Motor plans to add vehicle rental business to its corporate purpose, signaling a broader push into mobility subscription and vehicle leasing services.

Read the article

3/16/2026

Yale Padlock Maker to Axe New CEO Before He Starts

Financial Times (03/16/26) Barnes, Oliver

The maker of Yale and Master Lock padlocks is set to replace its incoming chief executive before his first day in the job as part of a détente with a hedge fund set up by a Trian co-founder. In order to stave off a proxy fight with investor Ed Garden, Fortune Brands Innovations (NYSE: FBIN) has committed to rerun its CEO search as well as adding Garden to its board of directors, according to people familiar with the matter. Garden Investments, the Trian co-founder’s new investment vehicle, privately nominated a slate of directors to Fortune Brands’ board earlier this year, pushing for sweeping corporate governance changes at the building products supplier to turn around its lackluster performance, the people said. Shares in Fortune Brands are down 32% over the past year, giving it a market capitalization of just under $5.2 billion as of Friday’s close. Its shares plummeted as much as 18% at the start of the year when it revealed poor quarterly results alongside the departure of its longtime CEO Nicholas Fink. Investors, including Garden, blamed the precipitous share price drop in part on the appointment of Amit Banati, as chief executive, pointing to his lack of experience in the building products sector. Banati had been Tylenol maker Kenvue’s (NYSE: KVUE) finance chief in the run-up to its sale to Kimberly-Clark (NASDAQ: KMB). He was due to assume the top job formally in May. Garden believed Fortune Brands had rushed Banati’s appointment and wanted the company to hunt for an alternative. Banati, who was also previously chief financial officer at packaged food group Kellanova before its sale to Mars, may also relinquish his board seat at Fortune Brands, which he had held since 2020, the people added. Last year, a record 32 CEOs of U.S. companies stepped down within a year of being engaged by investors, according to a Barclays (NYSE: BCS) report into shareholder activism. The settlement will allow Fortune Brands to avoid a messy and costly fight against Garden. As part of the deal, the padlock maker is also considering removing its staggered board structure, which meant only three directors out of 10 were up for election this year. A settlement is likely to be announced in the coming days but plans could shift, the people said. As one of the three co-founders of Trian Fund Management alongside billionaire Nelson Peltz, Garden has long been one of the leading lights among investors, helping to steer campaigns against corporate giants including General Electric (NYSE: GE) and Procter & Gamble (NYSE: PG) over nearly two decades at the firm. In 2023, Garden stepped down from Trian to launch family office investment vehicle Garden Investments, which would recycle his tried-and-tested activist playbook. Garden had already secured a board seat at kitchen equipment company Middleby (NASDAQ: MIDD) after building a 5% stake as well as successfully pushing it to spin off its food processing unit and divest control of its kitchen products unit behind the Aga stove. Garden is not prioritizing a break-up at Fortune Brands and instead believes the company could ride a wave of consolidation sweeping across the building products sector to growth, the people said. Serial dealmaker Brad Jacobs’ ambition to build a $50 billion building products group through dealmaking has triggered competitors such as Home Depot (NYSE: HD) and Lowe’s (NYSE: LOW) to strike large deals of their own.

Read the article

3/15/2026

Harwood Capital Pushes for Break-up of M&C Saatchi

The Times (London) (03/15/26) Powell, Emma

Harwood Capital is urging the board of M&C Saatchi (LON: SAA) to break up the advertising group, which could see it disappear from the public market entirely. Harwood Capital, which owns 6% of the group, is understood to believe that a piecemeal sale of M&C Saatchi’s disparate businesses, which range from traditional advertising to government advisory, could be a better way of unlocking value that is not currently being recognized. Harwood is thought to be following a similar playbook to its engagement at Centaur Media (LON: CAU), the former owner of The Lawyer, which has only one small business remaining after a disposal process in which it returned £64 million to shareholders. This is a tumultuous period for M&C Saatchi, which announced last week that Zaid Al-Qassab, who has been chief executive for less than two years, would stand down at the end of the month. The board is understood to have been looking for a few months at how to revive its valuation in the face of discontent from large shareholders, including Harwood. Vin Murria, a large shareholder who four years ago led a £254 million hostile takeover approach, has been appointed as a non-executive director alongside Nicholas Shott, a veteran investment banker. Shott, who helped take the Daily Mail and General Trust private in 2022, is understood to have been introduced to the board by Harwood. Dame Heather Rabbatts, the company’s non-executive chairwoman, has assumed interim leadership while the board searches for a new chief executive. M&C Saatchi is now valued at only £150 million, having lost 30% of its value over the past 12 months, as it battles falling revenue and broader fears that artificial intelligence could hit demand for some services across the marketing sector. In November it confirmed that it had received a £50 million takeover offer for its media planning and buying business from Brave Bison (LON: BBSN), a media and marketing company backed by Lord Ashcroft and (News Corp NASDAQ: NWS), the ultimate owner of The Times. M&C Saatchi was founded in 1995 by Maurice and Charles Saatchi after the brothers were ousted from Saatchi & Saatchi, the agency they had established and turned into one of the most famous names in global advertising. Harwood began building a stake in M&C Saatchi at the end of 2020, but surpassed the 5% threshold that forced it to declare its interest last December. Its stake of just under 6% makes it the fifth-largest investor in the company. Harwood is led by Christopher Mills, who played a key role in the sale of Hipgnosis, the music rights investment company, to Blackstone (NYSE: BX) in 2024. The M&C Saatchi position is held through Rockwood Strategic, one of Harwood Capital’s three investment trusts, which is run by Richard Staveley. He has previously led campaigns at STV (STVG.L), the Scottish commercial broadcaster, and Funding Circle (LON: FCH), the peer-to-peer lender.

Read the article

3/13/2026

Align Partners Presses DB Insurance on Governance, Shareholder Returns

Korea Times (03/13/26) Ji-hye, Jun

Align Partners Capital Management has ramped up pressure on DB Insurance (KRX: 005830) over shareholder value concerns by sending a second open letter to the insurer’s board, the fund said Friday. In the letter, issued Thursday in response to DB Insurance’s first shareholder communication on March 5, Align Partners urged the company to take stronger measures to enhance shareholder value and presented additional views on corporate governance reforms and shareholder return policies. The investor called for several changes, including adopting a management strategy based on return on required capital, strengthening shareholder return policies, improving internal transactions with group IT affiliate DB Inc., shifting to a joint trademark ownership structure, overhauling the executive compensation system, and reinforcing board independence. Align also raised new concerns regarding DB Insurance’s acquisition of U.S. insurer Fortegra. In September last year, DB Insurance signed a $1.65 billion deal to acquire Fortegra, the largest overseas takeover by a Korean insurer to date. The fund questioned the consistency of the company’s position, pointing out that while DB Insurance has taken a cautious stance on expanding shareholder payouts citing credit rating stability, it is simultaneously pursuing a large-scale acquisition despite Standard & Poor’s indicating that the deal could weigh on its credit rating. As part of its inquiry, Align requested detailed explanations about aspects of the Fortegra transaction, including the valuation basis and expected internal rate of return. Align acknowledged the insurer’s willingness to engage with shareholders, noting that management and the board had reviewed the proposals individually and responded within the designated timeframe, a move the fund said demonstrates a degree of openness to shareholder dialogue. Regarding Align’s letters, a DB Insurance official said the firm’s risk management framework is designed around efficiency and functions similarly to a return on required capital model. “We also recently decided to cancel 5.6% of our treasury shares acquired to boost shareholder value. We plan to continue reviewing and implementing further shareholder return measures, including complying with new treasury share cancellation requirements under the revised Commercial Act,” the official said. In an earlier letter to shareholders, DB Insurance CEO Jeong Jong-pyo stated, “The insurance industry must balance public responsibility, long-term risk management and the pursuit of shareholder value. We aim to strengthen shareholder trust through profitability-centered growth and more transparent corporate governance.”

Read the article

3/13/2026

Delivery Hero Investor Aspex Calls on CEO to Step Up Turnaround or Face Ouster

Reuters (03/13/26) Steitz, Christoph; Hübner, Alexander

A top Delivery Hero (DHER.DE) shareholder has threatened to push for a change of leadership unless the German online takeaway food group makes fast progress in an ongoing strategic review. Aspex Management said in a letter addressed to Delivery Hero CEO Niklas Oestberg, which was seen by Reuters, that there had been little progress and warned of further value destruction if not enough is done by the company. Hong Kong-based Aspex's comments add to pressure on Delivery Hero's management, which announced in December it would reassess its capital allocation and some country operations. Aspex said it doubted Delivery Hero was the best owner for selected businesses in Asia, the Middle East and Latin America, and that unless there was progress soon, it would "assess all legal courses of action available." These included "initiating steps that aim at ultimately changing the leadership of the company," it added. Oestberg said in a statement in response to the letter that the management board and non-executive supervisory board were "fully aligned" on the ongoing strategic review. "A number of processes and/or negotiations are currently being conducted and need to be handled with due care," the CEO added. He said the share price performance did not accurately reflect what has been achieved, and that management was working diligently to improve profitability and operational performance. In its letter, Aspex said the group was less profitable than rivals Uber (UBER.N), Grab (GRAB.O), Doordash (DASH.O), and Meituan (3690.HK). "Our expectation is that you will identify all those assets where Delivery Hero is not the best owner and operator, and the sale of such assets generates higher value for the company and for its shareholders ... than Delivery Hero continuing to operate such businesses," Aspex said. The sale of individual country divisions or minority holdings would not "constitute a believable and acceptable" outcome of the review, Aspex added. Aspex, Delivery Hero's third-largest investor with a 9.2% stake worth 474 million euros ($542 million), has been on the German company's shareholder register since 2020. The company attracted another investor's attention two years ago amid shareholder concerns about the group's debt and ability to generate enough cash from operations. The founder of investor Sachem Head Capital Management won a seat on the food delivery group's supervisory board in 2024.

Read the article

3/13/2026

New Investor Emerges at BlackLine After Engaged Deal brings M&A Vet to Board

Investing.com (03/13/26) Juricic, Luke

Blackline Inc (NASDAQ: BL) faces a fresh wave of scrutiny following a regulatory filing by San Francisco-based Fivespan Partners. The hedge fund disclosed a 5.1% stake in the software company on Thursday evening, just two days after a separate settlement with Engaged Capital. Fivespan, led by Managing Partner Dylan Haggart, spent approximately $138.6 million to accumulate over 3 million shares. According to the Schedule 13D filing, the firm intends to engage management on issues including "board composition" and "mergers and acquisitions strategy." The disclosure arrived shortly after BlackLine announced the appointment of technology M&A veteran Storm Duncan to its board and Strategic Committee. The committee is tasked with evaluating "strategic transactions involving the Company," Lead Independent Director David Henshall said in the announcement from Tuesday. Engaged Capital, which facilitated the board appointments through a cooperation agreement with BlackLine, emphasized the necessity of independent oversight for the software maker. "Storm has decades of experience in technology M&A and brings invaluable experience and independence to the Board and the Strategic Committee," stated Glenn W. Welling, founder of Engaged Capital. The intensified investor presence follows market reports from last year saying that the company previously bypassed a significant acquisition offer from SAP (NYSE: SAP). The enterprise software giant reportedly extended a $66 per share bid last spring, Reuters reported in October, a valuation nearly double the stock’s recent trading levels. The October report also said SAP was weighing a new bid for the company. BlackLine Chairman and CEO Owen Ryan maintains that the company is currently executing a clear plan focused on accelerating revenue growth. Ryan said on Tuesday, “We recognize that we have further to go, but the progress realized over the past few years and our focus on bringing our AI capabilities to our customers puts BlackLine in a strong position." Despite management's optimism, Fivespan noted in its filing that it believes BlackLine's securities are currently undervalued. The firm signaled it may seek further changes, including "whether it makes sense for a Fivespan employee to be on the Issuer's board of directors."

Read the article

3/12/2026

Align Partners Commits to Responsible Activism for Minority Shareholders

Korea Times (03/12/26) Whan-woo, Yi

Align Partners founder and CEO Lee Changhwan underscores the firm’s long-term commitment to strengthening minority shareholders’ rights as a homegrown hedge fund, reflecting the growing wave of shareholder activism in Korea’s stock market. This wave is gaining momentum in line with President Lee Jae Myung’s investor-friendly policies, with investors increasingly seeking to influence corporate decisions and governance, often by pressing management to adopt changes that enhance shareholder value. Yet, it has drawn mixed reactions — welcomed by those who see it as progress, but met with caution by those recalling some foreign hedge funds criticized for prioritizing quick, speculative gains over broader shareholder value. “Under the circumstances, I would like to stress that Align Partners naturally pursues long-term, responsible investments, unlike foreign hedge funds that tend to view Korea as just one market among many,” Lee said in an interview with The Korea Times at the company’s office in Seoul’s financial district of Yeouido, Wednesday. Backing up his argument, the CEO said Align Partners is “not inherently virtuous, but circumstances make it inevitable,” stressing compliance with local rules as a licensed asset manager registered under the Financial Services Commission and oversight by the Financial Supervisory Service. At the same time, he noted the demanding nature of long term commitment in Korea, where many listed companies have controlling shareholders with stakes exceeding 10 percent — a rare trait compared with markets like the United States or Japan. “Because of this ownership structure, it is not easy to carry out challenging initiatives with persistence over a long period. But regardless of such difficulties, I sincerely hope our actions will stand as positive examples contributing to the development of the capital market,” Lee said. “In this respect, there can be differences in how we operate compared with foreign funds.” Lee’s remarks came as Align Partners has emerged as a pioneering force among Korea-origin hedge funds, with assets under management reaching $1 billion in less than five years since its founding in September 2021. Before launching Align Partners, Lee worked at Goldman Sachs (GS) and KKR (KKR). Since its founding, it has executed shareholder activism campaigns across a range of high-profile companies, including K-pop powerhouse SM Entertainment (KOSDAQ: 041510), leading financial groups such as KB (KB), Shinhan (SHG), Hana (BKK: HANA), and Woori (NYSE: WF), as well as construction equipment manufacturer Doosan Bobcat (KRX: 241560). The company focuses on exploring opportunities arising from the “Korea discount,” a chronic undervaluation of Korean stocks that the president pledged to address after taking office in June 2025. The CEO welcomed the government’s capital market reform drive, noting three rounds of revisions to the Commercial Act aimed at enhancing corporate governance transparency, boosting shareholder returns and reinforcing the fiduciary responsibility of board members, among other measures. “These measures are something that should have existed naturally, but implementing the parliamentary amendments was a lengthy process and that is why the reform carries real significance,” he said. Asked whether the “Korea discount” has been resolved, Lee replied, “The discount phenomenon is starting to ease slightly, amid growing expectations and interest that corporate behavior will change.” The CEO noted that foreign capital, in particular, is “showing unprecedented levels of interest in Korea” and encouraged greater participation, highlighting that roughly 30 percent of Align Partners' investors are from abroad, mostly U.S. institutional investors. “I believe we are still in the early stages of capital market reform,” he said. “With numerous investment opportunities stemming from corporate governance improvements and restructuring across the broader financial landscape, I would suggest that now is the time to pay close attention to the Korean market.” Regarding the benchmark KOSPI surpassing milestones of 5,000 and even 6,000 points earlier this year, the CEO forecast that the main index is “still far from even halfway through its reform-driven growth cycle.” He referred to the case of Japan's Nikkei, which rose nearly seven- to eightfold over more than a decade of reform, saying, “Much of that sustained growth was driven by governance improvements.” Lee forecast that although the Iran conflict is weighing on the market and caution is warranted, governance reform still has “ample room to influence the stock cycle alongside external factors,” underscoring its potential to strengthen investor confidence and shape longer term market dynamics. To accelerate governance reform, the CEO emphasized three priorities. First, boards must change their behavior to honor shareholder rights and comply with measures such as the 3 percent rule, which limits dominant shareholders to just 3 percent of voting power when electing audit committee members. Secondly, corporate culture must move beyond the entrenched “owner” mindset and recognize that listed companies are collectively owned by all shareholders. Lastly, strong legal precedents should anchor fiduciary responsibilities, giving corporate law the weight of a constitutional principle within the business sphere. For companies in Align Partners' portfolios, the CEO said the firm has submitted shareholder proposals to six firms — DB Insurance (KRX: 005830), Coway (KRX: 021240), Gabia (KOSDAQ: 079940), Dentium (KRX: 145720), SoluM (KRX: 248070), and A Plus Asset Advisor (KRX: 244920)— all of which have general meetings of shareholders scheduled this month. DB Insurance will hold its meeting on March 20, while the others are scheduled to convene through the end of March. In particular, Align Partners is in a dispute with IT infrastructure and cloud services company Gabia, having filed an injunction to add a "say-on-pay" advisory shareholder proposal agenda at the general meeting on March 26. An advisory shareholder proposal, even if passed at a general meeting, is nonbinding — it cannot legally compel the board, but it signals shareholder sentiment, applies reputational pressure and can influence future governance practices.

Read the article

3/12/2026

Integer Appoints Two Directors in Cooperation With Irenic

Investing.com (03/12/26)

Integer Holdings Corporation (NYSE: ITGR) announced today the appointment of two independent directors to its board as part of a cooperation agreement with Irenic Capital Management, LP. James Flanagan, former Chief Operating Officer of PwC, and Aaron Kapito, a Partner at Politan Capital Management, have joined the board. The appointments are based on a press release statement from the company. Flanagan served as PwC’s COO from 2014 to 2021 and previously led the firm’s U.S. Financial Services Practice. He holds a B.S. in Accounting from Long Island University. Kapito co-founded Politan Capital Management in 2021 and previously worked at Lion Point Capital and Elliott Management. He earned a B.S. in Economics from the Wharton School and an M.B.A. from Harvard Business School. Under the cooperation agreement, Irenic agreed to customary standstill, voting, and confidentiality provisions. The full agreement will be filed with the Securities and Exchange Commission. Two existing directors will not stand for re-election at the company’s annual stockholder meeting, consistent with the board’s succession process. Integer’s CEO Payman Khales stated the company expects organic sales growth to return to market levels during 2026 and above-market levels in 2027. The company posted revenue of $1.85 billion over the last twelve months with analysts forecasting earnings per share of $6.51 for fiscal 2026. For deeper insights into Integer’s growth trajectory and financial health, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro for this and 1,400+ other U.S. equities. Adam Katz, Co-Founder and Chief Investment Officer of Irenic Capital Management, said the firm invested in Integer because it believes the company is positioned to capitalize on growth opportunities. Integer is a medical device contract development and manufacturing organization serving the cardio and vascular, neuromodulation, and cardiac rhythm management markets. The company has a market capitalization of $2.94 billion and currently trades at $85.47, which InvestingPro analysis suggests is undervalued relative to its Fair Value estimate. Goldman Sachs (GS) served as financial advisor to Integer, while Willkie Farr & Gallagher advised Irenic.

Read the article

3/12/2026

DOMA Perpetual Capital Management LLC Pushes Pacira BioSciences to Sell Itself

San Francisco Business Journal (03/12/26) Leuty, Ron

Calling spending by Pacira BioSciences Inc.'s (NASDAQ: PCRX) board "wasteful and unjustified," a hedge fund Wednesday called on fellow investors to elect three of its handpicked nominees that could lead to the company's sale. The move by DOMA Perpetual Capital Management LLC amps up a monthslong fight between the Miami asset management firm and Brisbane-based Pacira, a pain-treatment company that last year booked close to three-quarters of a billion dollars in revenue. Pacira hasn't yet announced the date of its annual shareholder meeting, but the proxy fight over the coming months is part of an on-again/off-again trend by biotech investors to wring money or control out of companies with a steady flow of revenue and solid cash reserves. The bottom line, DOMA said Wednesday, is that Pacira's board should work with bankers to sell the company, halt acquisitions of pipeline drugs and return capital to shareholders. "DOMA's aim is to generate profit for the company's shareholders, who have been forced to weather consistent year-over-year declines in the stock price while company expenses and management compensation have soared," according to the firm, which is led by Pedro Escudero. DOMA owns 7.1% of Pacira's outstanding shares. DOMA's board nominees are DOMA Chief Financial Officer Eric de Armas; Christopher Dennis, a psychiatrist with experience in behavioral health, digial health and opioid addiction; and Oliver Benton "Ben" Curtis III, a former federal prosecutor who advises on regulatory enforcement, internal investigations and more. Pacira leaders have met 12 times with DOMA, they said Wednesday, but the firm "has not provided any new insights regarding our strategy or operations that the company and the board are not already carefully evaluating and executing" as part of strategy it calls "5x30." That is a five-point plan targeting goals for 2030, including treating 3 million people with its products annually by the end of this decade. Pacira, led since early 2024 by former Genentech Inc. and Forma Therapeutics executive Frank Lee, has sold the injected, long-acting, nonopioid local anesthetic Exparel since its approval in April 2012. It was responsible for nearly 80% of Pacira's total revenue of $726.4 million last year. But that's just part of the 829-employee company's story. It bought Flexion Therapeutics in late 2021, adding the osteoarthritis treatment Zilretta, and by buying MyoScience Inc. in 2019 it added Iovera, a Food and Drug Administration-cleared handheld device that uses cold temperature to temporarily block nerve signals for up to three months. Its experimental gene therapy PCRX-201 is in a late-stage clinical trial to treat osteoarthritis of the knee as part of a push to develop more genetic medicines and it has a number of drugs in preclinical development, including one for osteoarthritis in dogs. The company has moved to cut costs and return cash to shareholders. For example, it decommissioned a 45-liter Exparel batch manufacturing suite in San Diego, leading to 71 layoffs last year, in favor of two 200-liter suites in San Diego and the United Kingdom. And it said it repurchased $150 million in stock, reducing its outstanding shares from 47 million to 41 million. But the heart of Pacira, which had $238.4 million in cash, equivalents and investments at the end of last year, is Exparel, and DOMA said has been "undermined by management's strategic and operational execution." The company faces competition from a generic version of the drug, which was approved by the FDA in August 2024.

Read the article